Results 21 to 30 of about 4,368 (233)

Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study [PDF]

Journal of Clinical Endocrinology and Metabolism, 2019
INTRODUCTION The treatment of acromegaly resistant to first and second line therapies may be extremely challenging. AIM, PATIENTS AND METHODS To describe our patients successfully treated with a combination therapy of Pasireotide LAR and Pegvisomant ...
Sabrina Chiloiro, Chiara Bima, Tommaso Tartaglione, Antonella Giampietro, Marco Gessi, Liverana Lauretti, Carmelo Anile, Cesare Colosimo, Guido Rindi, Alfredo Pontecorvi, Laura De Marinis, Antonio Bianchi   +11 more
openalex   +2 more sources

Long-term Pegvisomant Therapy of Acromegaly: Effects on Bone Density, Turnover and Microstructure Using HRpQCT. [PDF]

J Endocr Soc
Context Fracture rate is increased in patients with active acromegaly and those in remission. Abnormalities of bone microstructure are present in patients with active disease and persist despite biochemical control after surgery.
Kuker AP, Agarwal S, Shane E, Bicca J, Geer EB, Cremers S, Dworakowski E, Cohen A, Nickolas TL, Stein EM, Freda PU.   +10 more
europepmc   +2 more sources

The place of medical treatment of acromegaly in Serbia: Current status [PDF]

Vojnosanitetski Pregled, 2021
nema
Doknić Mirjana, Stojanović Marko
doaj   +1 more source

Cost-Utility of Acromegaly Pharmacological Treatments in a French Context

Frontiers in Endocrinology, 2021
ObjectiveEfficacy of pharmacological treatments for acromegaly has been assessed in many clinical or real-world studies but no study was interested in economics evaluation of these treatments in France.
Thierry Brue, Thierry Brue, Philippe Chanson, Patrice Rodien, Brigitte Delemer, Delphine Drui, Lucile Marié, Laurène Juban, Lara Salvi, Robin Henocque, Gérald Raverot   +10 more
doaj   +1 more source

Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs [PDF]

Journal of Clinical Endocrinology and Metabolism, 2019
PURPOSE Osteopathy is an emerging complication of acromegaly. In somatostatin receptor ligands (SRL)-resistant patients, Pegvisomant (PegV) and Pasireotide LAR (Pasi) are used for acromegaly treatment, but their effect on skeletal health is still not ...
Sabrina Chiloiro, Antonella Giampietro, Stefano Frara, Chiara Bima, Federico Donfrancesco, Cara M. Fleseriu, Alfredo Pontecorvi, Andrea Giustina, Maria Fleseriu, Laura De Marinis, Antonio Bianchi   +10 more
openalex   +2 more sources

Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience

Journal of Endocrinological Investigation, 2023
Purpose Pegvisomant (PEG) efficaciously controls IGF-I excess in acromegaly and possesses a positive impact on glucose metabolism. Data on very prolonged PEG treatment are still limited, therefore, we investigated the effects of 10-years PEG on disease ...
R. Pirchio, R. Auriemma, M. Montini, A. Vergura, R. Pivonello, A. Colao   +5 more
semanticscholar   +1 more source

Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience

Pituitary, 2022
Roberto Salvatori, Pietro Maffei, Susan M. Webb, Thierry Brue, Jane Loftus, Srinivas Rao Valluri, Roy Gomez, Michael P. Wajnrajch, Maria Fleseriu   +8 more
openalex   +3 more sources

Pegvisomant for acromegaly: does it always works? [PDF]

Archives of Endocrinology and Metabolism, 2019
Sebastian J. Neggers, Aart J. van der Lely   +1 more
doaj   +2 more sources

Effective Long-term Pediatric Pegvisomant Monotherapy to Final Height in X-linked Acrogigantism

JCEM Case Reports, 2023
X-linked acrogigantism (X-LAG) is characterized by extreme tall stature from early childhood resulting from duplication of the GPR101 gene, in turn resulting in GH excess. Most cases present with pituitary tumors secreting GH and prolactin.
Christine P Burren, Georgina Williams, E. Coxson, Márta Korbonits   +3 more
semanticscholar   +1 more source

Experiense of treatment with a growth hormone receptor antagonist in patients with hereditary form of acromegaly: clinical cases

Ожирение и метаболизм, 2022
Acromegaly is a severe neuroendocrine disease caused by chronic excessive production of somatotropic hormone (STH), characterized by specific changes in appearance, metabolic disorders.
L. K. Dzeranova, A. V. Dorovskikh, E. A. Pigarova, E. G. Przhiyalkovskaya, A. S. Shutova, M. I. Yevloyeva, A. Yu. Grigoriev, V. N. Azizyan, O. V. Ivashchenko   +8 more
doaj   +1 more source